MPI Research Integration Update

In April 2018, Charles River Laboratories completed the acquisition of MPI Research, a premier nonclinical contract research organization (CRO). The acquisition enhances Charles River’s position as a leading global early-stage CRO by strengthening our ability to partner with clients across the drug discovery and development continuum. MPI Research will continue to operate under our Safety Assessment umbrella, providing critical services, new capabilities, and expanded capacity for the growing biotechnology industry.

 

Integration Update

 

Watch as our leaders discuss the positive impacts on our staff and operations, commercial successes, and the value our enhanced team brings to your programs.

The addition of these experts and scientists from MPI Research brings fresh perspectives and years of experience to our growing Safety Assessment team. Read more about Mattawan

Accelerate your drug development program timelines with our expanded network of scientists. Reach out to our team to speak with an expert and to plan your next project. Start planning now